Private Equity Fund Investments
Carlyle to invest in pharma firm Viyash
Hyderabad-based Viyash Life Sciences is to raise funding from US-headquartered PE investor Carlyle Group to set up a generic pharmaceutical platform. Citadel Management Consulting, a Hyderabad-based advisory firm, acted as an advisor to Carlyle. The investment is routed through CA Hull Investments, an affiliated entity of Carlyle unit, CAP V Mauritius Limited. Viyash Viyash is co-founded by Dr. Hari Babu (previously Global COO of Mylan) and Dr. Srihari Raju Kalidindi (previously ED of Laurus Labs). It is a manufacturer of API (active pharmaceutical ingredients) intermediates. Carlyle had first partnered with Viyash in June 2021, during the latter's acquisition of a majority stake in Symed Labs, a manufacturer of niche APIs. Viyash has also acquired a controlling stake in Appco Pharma LLC, a formulations player focused on the US market, which will help expand access to US generics market and formulation capabilities.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
